Drugs / mRNA CR-04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05972993 | Aug 2023 → May 2024 | COVID-19 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA CR-04 | “Part A, Group 1: mRNA CR-04 10 µg” NCT05972993 ↗ |
| Route | Intramuscular | “mRNA-CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.” NCT05972993 ↗ |